Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.

Trial Profile

Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Maruishi Pharmaceutical
  • Most Recent Events

    • 11 Jul 2018 According to Cara Therapeutics data from this study were presented at the 2017 American Society of Nephrologys Annual Meeting.
    • 01 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top